Summit Therapeutics
SMMT
9.95
-0.62
-5.87%
Summit Therapeutics
US · SMMT
#1207 by market cap
Listed 2015
9.95
-0.62
-5.87%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $43Market Newswire · 2026/10/26
-
Rating change
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $37Market Newswire · 2026/11/5
-
Rating change
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/11/6
-
Rating change
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $43Market Newswire · 2026/9/30
-
Rating change
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/11/4
-
Leerink Partners Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Announces Target Price $11Market Newswire · 2026/11/19
-
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $42Market Newswire · 2026/11/17
-
Rating change
Jefferies Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Raises Target Price to $25Market Newswire · 2026/9/9
-
Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Cuts Target Price to $8.3Market Newswire · 2026/11/18
-
Rating change
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/9/14
-
Rating change
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/11
-
Rating change
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/11/5
-
Rating change
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20Market Newswire · 2026/10/1
-
Rating change
UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33Market Newswire · 2026/10/26
-
Rating change
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $18 to $42Market Newswire · 2026/11/16
-
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold RatingMarket Newswire · 2026/11/18
-
Leerink Partners Upgrades Summit Therapeutics(SMMT.US) to Hold RatingMarket Newswire · 2026/11/19
-
Rating change
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/11/6
-
Rating change
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18Market Newswire · 2026/9/21
-
Rating change
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41Market Newswire · 2026/9/14
-
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold RatingMarket Newswire · 2026/11/5
-
Rating change
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/8/27
-
Rating change
Wolfe Research Initiates Summit Therapeutics(SMMT.US) With Hold RatingMarket Newswire · 2026/8/17
-
Rating change
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $38Market Newswire · 2026/7/29
-
Rating change
Clear Street Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31Market Newswire · 2026/9/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.
Summit Therapeutics discussion 0 comments